Publicis acquires LiveRamp in $2.2bn deal to boost data and AI

Publicis Groupe  to acquire US-based data and identity platform LiveRamp for $2.2bn, expanding its capabilities in audience targeting, analytics, and AI-driven personalisation. The deal is expected to close later in 2026, pending regulatory approvals. 

The acquisition continues a broader strategy from Publicis that has increasingly focused on buying technology and data infrastructure platforms rather than traditional agencies. In March 2025, solli reported on Publicis’s acquisition of Lotame, the independent data marketplace and identity solution provider, further strengthening its position in audience intelligence and identity-driven media capabilities. 

LiveRamp’s core offerings centre on data integration and identity resolution across digital channels, positioning its technology as critical to the future of AI-powered targeting and measurement. Publicis’s latest move signals heightened demand for solutions that enable marketers, including those in pharma, to connect first-party data with media buying, analytics, and HCP engagement strategies. 

For pharmaceutical marketers,as privacy regulations tighten globally, identity resolution is becoming essential to maintain accuracy in both DTC and HCP campaigns. LiveRamp is already widely used across healthcare advertising, enabling brands, agencies, and publishers to connect datasets from CRM systems, claims data, media exposure, and real-world evidence. Publicis has stated the acquisition will ‘accelerate data co-creation for smarter agents,’ pointing toward deeper integration between its healthcare agency network and ad tech infrastructure. 

The acquisition also reinforces an industry-wide shift where major holding companies are building proprietary data ecosystems rather than relying solely on external platforms. Instead of scaling through agency consolidation alone, Publicis appears increasingly focused on owning the underlying technology powering audience identity, measurement, and AI-enabled optimisation.

For pharma media, where compliance, interoperability, and closed-loop measurement are becoming more important, this signals a growing convergence between media operations, data infrastructure, and healthcare-specific analytics. 

What the acquisition will ultimately mean for existing pharma media clients of LiveRamp remains less clear. Many healthcare brands, publishers, and agencies across the ecosystem currently rely on LiveRamp as a relatively neutral interoperability layer between platforms and partners.

Industry observers will be watching closely to see how Publicis balances platform ownership with maintaining trust and accessibility across competing agency groups and independent healthcare media partners. 

The acquisition comes at a time when more pharma brands are demanding granular targeting and measurable omnichannel engagement across both HCP and consumer campaigns. LiveRamp’s technology could offer greater scale and speed for aligning pharma brand content, medical education, and promotional activity across digital touchpoints, particularly as AI-driven media planning and activation accelerate. 

solli’s Final Thoughts 

Publicis’s acquisition of LiveRamp further confirms that the next battleground in pharma media is infrastructure, not simply inventory. Identity, interoperability, and measurement are becoming central to how healthcare campaigns are planned, activated, and optimised in an AI-driven ecosystem. 

Following acquisitions such as Lotame and now LiveRamp, Publicis is steadily assembling a technology stack designed to support first-party data activation, AI-powered audience orchestration, and privacy-conscious measurement at scale.

For pharma marketers, this raises important questions around platform dependency, data ownership, and how neutral interoperability layers may evolve as holding companies increasingly control the infrastructure powering healthcare media execution.